Two apolipoprotein L1 (APOL1) gene variants, which likely evolved to protect individuals from African sleeping sickness, are strongly associated with non-diabetic kidney disease in individuals with recent African ancestry. Consistent with its role in trypanosome killing, the pro-death APOL1 protein is toxic to most cells, but its mechanism of cell death is poorly understood and little is known regarding its intracellular trafficking and secretion. Because liver appears to be the main source of circulating APOL1, we examined its secretory behavior and mechanism of toxicity in hepatoma cells and primary human hepatocytes. APOL1 is poorly secreted in vitro, even in the presence of chemical chaperones; however, it is efficiently secreted in wild-type transgenic mice, suggesting that APOL1 secretion has specialized requirements that cultured cells fail to support. In hepatoma cells, inducible expression of APOL1 and its risk variants promoted cell death, with the G1 variant displaying the highest degree of toxicity. To explore the basis for APOL1-mediated cell toxicity, ER stress, pyroptosis, autophagy, and apoptosis were examined.
INTRODUCTION
Coding variants within the apolipoprotein L1 gene (APOL1) are present in high frequency among individuals who possess recent African ancestry and demonstrate among the highest odds ratios yet reported for association with complex kidney disease (1, 2) . APOL1 renal risk variants also associate with reduced levels of calcified atherosclerotic plaque in coronary and carotid arteries (3, 4) .
APOL1 nephropathy risk variants have undergone positive selection in sub-Saharan
Africa due to protection from Trypanosoma brucei rhodesiense, a cause of African sleeping sickness (5) . The mechanism whereby APOL1 risk variant (G1 and G2) proteins kill trypanosomes is well-understood, and reflects APOL1 protein uptake by parasites, trafficking to the lysosome, and an acidic pH-induced conformational change with subsequent APOL1 protein insertion into lysosomal membranes. Chloride transport ensues via the APOL1 channel with osmotic swelling and eventual lysosomal rupture leading to parasite death. In contrast, the mechanism(s) whereby APOL1 renal risk variants produce progressive, non-diabetic nephropathy remain poorly understood. Moreover, the basic biology of APOL1 proteins has not yet been elucidated and will be of utmost importance to define its role in human diseases. We and others have shown that APOL1 mRNA and protein are present in podocytes, renal tubule cells, and glomerular endothelial cells, but not mesangial cells (6, 7) . APOL1 protein is also present in the medium was collected and cell debris were cleared by centrifugation and adjusted to 1× lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 10 µg/mL pepstatin, and 10 µg/mL leupeptin). Cells were placed on ice and lysed in lysis buffer containing protease inhibitors.
For metabolic radiolabeling of APOL1 in transgenic mice, mice were sedated by isoflurane inhalation and administered 200 µCi [ 35 S]-Met/Cys by retro-orbital injection. Blood was collected in heparinized capillary tubes by retro-orbital bleeding at 0 (before injection), 30, 60, 120, or 180 min post-injection. Plasma (20 µL) was diluted into 1 mL of 1× lysis buffer (see above).
Samples described above were adjusted to 0.2% bovine serum albumin (BSA) using concentrated stocks and then subjected to immunoprecipitation by addition of either 2 µL rabbit anti-APOL1 antibody (Sigma-Aldrich; St. Louis, MO, HPA018885), 5 µL rabbit anti-maltose binding protein-APOL1 fusion protein serum (APOL1-MBP antibody), or 5 µL anti-mouse serum albumin antibody (Abcam; Cambridge, MA; AB34807). After 18 h incubation with rotation at 4°C, 20 µL of protein G-Sepharose (50:50 slurry; Amersham Biosciences; Buckinghamshire, England) was added to each sample followed by an additional 3 h incubation. Beads were collected by centrifugation at 10,000 rpm for 10 s and washed three times with lysis buffer.
Proteins were eluted from the beads by heating in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 100°C for 5 min and fractionated by 12% SDS-PAGE. Gels were then dried and visualized using a FujiFilm BAS-5000 Phosphorimager. In the indicated experiments, band intensities were quantified using MultiGauge software. 
Immunoblot analysis
Cells were lysed on ice with lysis buffer, centrifuged at 10,000 x g for 5 min and supernatants mixed with concentrated SDS-PAGE sample buffer. Proteins were separated by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. After incubation with primary and horse radish peroxidase (HRP)-conjugated secondary antibodies, membranes were incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific; Waltham, MA, 34078) followed by direct visualization using a Fujifilm LAS-3000 imager. In some cases, band intensities were quantified using MultiGauge software. APOL1 protein was detected using the rabbit anti-APOL1 antibody (Sigma-Aldrich; HPA01885). Other antibodies used included rabbit polyclonal to GRP78 (BiP; Abcam; ab21685), and anti-LC3 (NOVUS; St. Louis, MO; NB100-2200).
APOL1 toxicity assay
G0 APOL1, and G1 and G2 renal disease variants were stably transfected into McA cells and incubated under varying conditions, as described in 'Results" for the indicated time periods. G0
and disease variants (G1, G2) APOL1-induced cell death was directly visualized by microscopy and quantified by measuring cellular lactate dehydrogenase (LDH) release into the medium using a cytotoxicity assay kit (Pierce; 88954) according to the manufacturer's instructions. 
Data analysis
Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test to determine significant differences among groups. A Student's t-test was performed to determine statistical significance between two groups. A P value < 0.05 was considered to indicate statistical significance. Values are represented as the mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism software.
RESULTS

Expression and secretion of APOL1 in COS7 cells
The consequences of APOL1 expression were initially examined by expressing the G0 isoform in COS7 cells. Twenty-four hours after transfection, cells were radiolabeled with [ 35 S]-Met for 4 h, and cell and media samples were subjected to immunoprecipitation using rabbit anti-APOL1. As displayed in Fig. 1A , APOL1-transfected cell and media samples revealed three bands by SDS-PAGE, which were not detected in the mock-transfected control (compare lanes 1 and 2 to lanes [3] [4] [5] [6] [7] [8] . Based on molecular weight, the upper band represents the full-length 46-kDa form of APOL1; the lower bands likely correspond to degradation products. As APOL1 is believed to associate primarily with lipoprotein particles in human plasma and is easily degraded during storage (data not shown), it is possible that secreted APOL1 could be degraded in labeling medium lacking FBS; another possibility is that APOL1 may require additional time for Hence, we concluded that the inefficient APOL1secretion likely relates to its inefficient folding and/or trafficking within the ER and Golgi.
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In vivo APOL1 secretion is more efficient than in vitro secretion from cell lines or cultured primary hepatocytes
We next determined whether the cell type used for APOL1 expression impacted its secretory efficiency. Since APOL1 is abundantly expressed in the liver, which is likely the primary source of circulating APOL1 (8), McA rat hepatoma cells were stably transfected with APOL1 G0, G1
and G2 variants under the control of a Tet-inducible promoter, using methods described previously (14, 15) . When cells were induced with Dox for 16 h and metabolically radiolabeled with [ 35 S]-Met for 4 h, abundant protein was detected in cell pellets; however, the amount observed in media samples remained very low ( Fig. 2A and B, lanes 1-6), demonstrating that cell lines of hepatic origin are also incapable of efficient APOL1 secretion. Several chemical chaperones, including 4-phenyl butyric acid (4-PBA; Sigma-Aldrich; 10 mM) and trimethylamine N-oxide (TMAO; Sigma-Aldrich; 150 mM), have been shown to enhance the folding and secretion of mutant or poorly folded and secreted proteins (16, 17) . However, neither chemical chaperone was capable of enhancing secretion of the G0, G1 or G2 APOL1 isoforms ( Fig. 2A and B, lanes 7-12).
APOL1 secretion was further examined in primary human hepatocytes to determine whether the poor APOL1 secretion efficiency is specific to immortalized cell lines. After plating, primary human hepatocytes were subjected to continuous radiolabeling with [
S]-Met and [ S]-
Cys for 4 h. Cell lysates and medium were then subjected to immunoprecipitation with anti-APOL1 and anti-albumin antibodies. Results revealed that APOL1 remained almost exclusively in the cell lysate, whereas human serum albumin (HSA) was efficiently secreted into media ( Fig.   3A) , demonstrating that APOL1 is also poorly secreted from primary cultured hepatocytes.
To determine whether the inefficient secretion of APOL1 is also observed in vivo, we examined the secretion of human APOL1 in liver-specific transgenic mice. appearance in plasma were similar to that of albumin (Fig. 3C) , suggesting that the inefficient secretion of APOL1 observed previously is likely caused by in vitro culture conditions.
APOL1 may be targeted for proteasomal degradation
Inefficient secretion is a characteristic of proteins that are also targeted for pre-secretory degradation, likely due to an inherent property of the protein, such as inefficient folding or lack of an essential binding partner or cofactor (18) . We therefore explored whether APOL1 undergoes As shown in Fig. 4A and B, no significant differences were observed in cellular or media APOL1 abundance upon incubation with leupeptin. In contrast, MG132 increased the abundance of cellular APOL1 protein ( Fig. 4C and D) . While G0 appeared to be the most highly stabilized, MG132 also facilitated the accumulation of both the G1 and G2 isoforms. While the cellular abundance of each form of APOL1 increased under conditions of proteasome inhibition, no increase in secretion was observed.
As the retrograde translocation of proteins from the ER to cytosol is a prerequisite for proteasome-mediated ER-associated degradation (ERAD), it was also important to determine whether APOL1 is localized to the ER. Fluorescence microscopy revealed that APOL1 colocalized with a known ER marker, protein disulfide isomerase (PDI), in stably transfected
McA cells following induction with Dox for 10 h (Fig. 5A and B) . Hence, it appears that APOL1 is retained within the ER and does not traffic efficiently to the Golgi within this time period, consistent with the lack of APOL1 protein in media fractions from transfected cells.
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Cellular toxicity of APOL1 constructs G0 APOL1 induces cell death in several tissues (19) . We found Dox-induced expression of all forms of APOL1 in transfected McA cells caused cell death, as evidenced by the loss of cell adherence and cell number after 22 h of Dox induction ( Figure 6A) . To compare the cell deathinducing capability among G0 and disease variant APOL1 isoforms at similar levels of protein expression (Fig. 6B) , an LDH release assay was performed. McA cells expressing G0 and G2
showed comparable levels of LDH release, whereas induction of the G1 variant led to the highest LDH release (Fig. 6C) . While both APOL1 variants associate with kidney disease, our results suggest that the G1 variant is more toxic than G2, which retains similar cellular toxicity as that of G0 APOL1.
APOL1 expression does not activate the ER stress pathways
ER stress, also referred to as the unfolded protein response, constitutes an important mediator of cell death. As APOL1 G0, G1 and G2 are poorly secreted in vitro (Fig. 1, 2 and 3 ) and are targeted for proteasomal degradation (Fig. 4) , we next explored whether APOL1 activates ER stress. As a measure of ER stress, cleavage of XBP-1 mRNA by RT-PCR was examined. Upon relative to the non-spliced form (479 bp) (Fig. 7A) . In contrast, treatment with tunicamycin (2 µg/ml), a robust inducer of ER stress, caused significant induction of XBP1 splicing (Fig. 7A) .
Consistent with these findings, tunicamycin induced the accumulation of BiP, a known transcriptional target of activated XBP1, whereas BiP was not induced by Dox-induced expression of the G0, G1 or G2 forms of APOL1. (Fig. 7B, C) , suggesting that ER stress is not likely a cause of APOL1-induced cell death. Interestingly, treatment with tunicamycin significantly reduced the cellular toxicity of all three APOL1 forms relative to untreated cells (Fig. 7D, +Dox) . This cell protection may result from reduced APOL1 mRNA and protein expression after tunicamycin treatment, which is a known adaptation caused by the ER stress response (21) (Fig. 7E) .
APOL1 toxicity is regulated by autophagy
Wild-type (G0) APOL1 has been reported to trigger autophagy-mediated cell death (19, 22) . To determine whether autophagy is involved in cytotoxicity of APOL1 and its disease variants in our inducible cell lines, we first performed Western blot analysis to examine LC3-II accumulation, a reliable marker of autophagy. As shown in Figure 8A , Dox-induced stably-transfected McA cells
showed an increased amount of LC3-II induction relative to untransfected cells, suggesting that autophagy contributes to APOL1 G0-and APOL1 nephropathy variant-induced cell death.
Considering that the lower level of G1 mutant expression induced the highest amount of LC3-II, it is likely that the G1 variant is more toxic to cells than G0 or G2, consistent with the LDH release assay results reported above (Fig. 6C) . To confirm that autophagy is the cause of subsequent cell death, the autophagy inhibitor 3-methyladenine (3MA) was employed. Addition of 5 mM 3MA to induced cells attenuated APOL1-induced cell death, as evidenced by decreased LDH release (Fig. 8B) , further indicating that APOL1-induced cell death is, at least partially, caused by activation of autophagy.
Pyroptosis may also contribute to APOL1-induced cell death
APOL1 was identified in 2009 as a novel BH3-only protein (19) . BH3-only proteins represent the pro-apoptotic subclass within the BCL-2 family of apoptosis regulators. We therefore explored a potential role for apoptosis in mediating cell injury and death mediated by APOL1 and its G1 and G2 variants. Following 18 h of Dox induction, flow cytometric analysis of annexin V/propidium iodide (PI) stained cells revealed a significant increase in double-positive (Anx + PI + ) stained stably-transfected APOL1 G1-expressing cells, relative to the G0 and G2 isoforms (Fig. 9) , indicating a role for late apoptosis in APOL1 G1-induced cell death. However, no difference was observed between the parental McA cells and G0 or G2 isoforms. Attempts to confirm increased apoptosis in the G1 isoform by cleaved caspase-3 Western blot analysis were unsuccessful due to lack of a specific rat antibody. Interestingly, flow cytometry also revealed significant alterations in cell size/morphology in all APOL1-overexpressing populations following Dox induction, evidenced by an increase in the percent of small cells and concomitant decrease in large cells, indicative of cells undergoing or likely to undergo autophagic cell death (19) (Fig. 10) .
Pyroptosis is another type of programmed cell death triggered by caspase-1 following its activation by various inflammasomes, resulting in cellular lysis and release of cytosolic contents into the extracellular space (23, 24). To test whether pyroptosis is involved in APOL1-induced cell death, cells were incubated with caspase-1 inhibitor Z-YVAD-FMK during APOL1
induction. Interestingly, caspase-1 inhibition significantly decreased LDH release from APOL1-overexpressing cells relative to control cells (Fig. 11) , suggesting that caspase-1-induced pyroptosis may also contribute to APOL1-induced cytotoxicity.
DISCUSSION
Although the mechanism by which APOL1 risk variant proteins kill trypanosomes has been defined, the role of these variants in development of APOL1-associated diseases remains poorly understood. Furthermore, expression of G0 (wild-type) APOL1 appears to induce programmed cell death, although the exact mechanism has yet to be determined. Prior reports on the main mechanism of APOL1-induced cell death implicated the autophagic pathway (19, 22) , while others have shown that APOL1 induces podocyte necrosis by compromising lysosomal membrane permeability (25). Major goals of the present study were to elucidate the pathway of APOL1-induced cell death, as well as general outcomes of APOL1 expression in liver cells, since the liver is the primary source of APOL1 proteins and exhibits highly efficient secretory activity.
The intracellular trafficking of APOL1 was assessed to gain a better understanding of its potential roles in human disorders. APOL1 is inefficiently secreted in COS7 and McA cell lines, as well as cultured primary human hepatocytes. Furthermore, inefficient secretion is not likely caused by the signal peptide, since replacement with the human serum albumin signal peptide failed to improve APOL1 secretion from COS7 cells. Poor secretion and stabilization of APOL1 by proteasome inhibitors led us to consider the possibility that, under the cell culture conditions employed, APOL1 undergoes incomplete folding and/or assembly, making it a substrate for ERAD and possible activation of ER stress pathways.
To determine whether APOL1 proteins are targeted for ERAD, we examined colocalization with the ER marker PDI. Immunofluorescence microscopy confirmed that APOL1 is predominantly localized within the ER and excluded from the Golgi, thereby explaining why it is not secreted within the time periods examined. Intracellular abundance of APOL1 and its variants was increased by incubation of cells with the proteasome inhibitor, MG132. Hence, both transfected APOL1 and endogenous APOL1 expressed in human hepatocytes fails to achieve a transport-competent form, and is therefore retained in the ER and subjected to retrograde Indeed, treatment with tunicamycin, a potent inducer of ER stress, protected cells from APOL1-induced cell death, likely by decreasing APOL1 mRNA and protein levels.
As APOL1 expression did not appear to induce ER stress, we aimed to clarify the mechanism of cell death associated with expression of APOL1 proteins. We concluded that all forms of APOL1 are toxic, although based on LDH release assays, the G1 variant appeared to be the most cytotoxic among the three variants examined. APOL1-expressing cells treated with 3MA exhibited a significant decrease in toxicity, suggesting that autophagy is a potential mechanism for APOL1-induced toxicity, in agreement with prior reports (19, 22) . Moreover, stable expression of G0, G1 and G2 APOL1 clearly induced autophagy, as demonstrated by increased LC3-II production. Consistent with differential toxicity among APOL1 isoforms observed by LDH release assays, the G1 variant induced the highest accumulation of LC3-II.
While APOL1 was previously identified as a BH3-only protein, no evidence has suggested that APOL1-induced toxicity is directly related to apoptosis. However, it is possible, as for other BH3-only family members, that APOL1 may regulate the apoptotic pathway. Although our data did not indicate that apoptosis was the major mechanism of cell death in APOL1-expressing McA cells, as the percentage of annexin V + /PI + cells increased from only ~2% to 4%, a significant increase in late-stage apoptosis associated with the G1 isoform relative to the other APOL1 variants was observed following Dox induction. Due to sensitivities to both time and dose of APOL1 regarding cellular toxicity, it will be important to examine the role of apoptosis in APOL1-expressing cells at additional time points.
The in vitro and in vivo studies on APOL1 secretion and toxicity presented herein aimed to shed light on the consequences of APOL1 risk variant overexpression. Our results strongly suggest that cell lines, such as those used in this study, likely retain APOL1 proteins due to inefficient secretion, resulting in cellular toxicity. In contrast, APOL1 is efficiently secreted by hepatocytes in vivo, as evidenced by our hepatocyte-specific APOL1 transgenic mouse model, which likely explains why hepatic toxicity is not observed in African Americans with APOL1 renal risk variants. Thus, cells with high secretory capacity may escape the toxic effects of APOL1 expression, whereas those with low secretory capacity do not. Secreted APOL1 proteins may play an important role in the reduced risk of calcified atherosclerotic plaque (subclinical atherosclerosis) in African Americans with two APOL1 renal risk variants (3, 4) . Results may further improve our understanding of the potential mechanisms of APOL1-associated pathology in this population. While significant differences in toxicity were observed among the G0 and risk variant forms of APOL1 (notably G1), the mechanism of renal risk variant-induced kidney damage requires further study.
Taken together, the current results provide new insights into the intracellular trafficking and secretion of APOL1 and the mechanism of APOL1-induced cell death. While all APOL1
isoforms are inefficiently secreted in vitro, we showed that APOL1 is efficiently secreted in G0 APOL1 transgenic mice, suggesting the presence of an in vivo binding partner/cofactor, which will be an important factor to consider in future studies on APOL1 secretion and function. Upon examining the major pathways of programmed cell death, including ER stress, pyroptosis, autophagy, and apoptosis, our results indicate that autophagy represents the main mechanism of APOL1-induced hepatic cell death. Apoptosis and/or pyroptosis may also contribute, albeit to far lesser extents. Additional studies are required to further elucidate the mechanism(s) of APOL1-induced cell death and identify potential differences among APOL1 variant proteins that ultimately contribute to progression of non-diabetic nephropathy in African Americans with two APOL1 renal risk variants. Figure 11 
